by Stacey Hawkins | May 5, 2020 | Oncology
Despite restricted access to parks and beaches due to the COVID-19 pandemic, people everywhere continue to seek solace in outdoor activities, enjoying a walk through the neighborhood or a cold drink on a hot afternoon in a sunny backyard. Fresh air and sunlight are... 
by Stacey Hawkins | Apr 21, 2020 | Oncology
Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of treatment, while inroads against... 
by Stacey Hawkins | Sep 26, 2019 | Oncology
The Elusive Cancer Vaccine Like unicorns, the fountain of youth and calorie-free chocolate, cancer vaccines have long proven elusive. But the emergence of a new crop of biotech companies makes it clear that a cancer vaccine is no myth. The latest advances in genomics... 
by Stacey Hawkins | Jun 26, 2019 | Oncology
Keeping Cancer In The Crosshairs With Targeted Therapies One of the biggest stories in last week’s biotech news headlines was Pfizer’s (New York, NY) acquisition of Array Biopharma (Boulder, CO) for the tidy sum of $11 billion. Array specializes in targeted cancer... 
by Stacey Hawkins | Feb 26, 2019 | Oncology
PARP1 INHIBITORs PARP1 inhibitors are back in the headlines this week, as Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza posted positive Phase III results from a trial with pancreatic cancer patients—a notoriously difficult... 
by Stacey Hawkins | Jul 5, 2018 | Oncology
Breaking Down Lung Cancer The hit TV series Breaking Bad features anti-hero Walter White, who starts out as a sympathetic character: a mild-mannered high school chemistry teacher with a nagging cough that turns out to be lung cancer. Money problems precipitated...
